Table of Contents
- Trial overview
- Pain and musculoskeletal studies
- Ear and eye studies
- Skin and soft tissue studies
- Pediatric and surgical studies
- What the trials measure
- Who the trials include
Trial overview
These studies are testing Triamcinolone Acetonide in different clinical settings, not as a general drug description but as a study treatment in specific patient groups.[1]
Most of the trials in the source data are Phase 3 studies, with a smaller number of Phase 2 studies and one low-intervention trial.[1][2]
The trials are mostly interventional studies, which means the research team assigns a treatment or procedure and then measures the results.[1]
Pain and musculoskeletal studies
Several trials study pain and movement problems, including fibromyalgia-related trapezius pain, frozen shoulder, chronic shoulder pain, rheumatoid arthritis, and thumb base osteoarthritis.[1]
In the fibromyalgia study, researchers compare regional treatment for trapezius pain using bupivacaine and Triamcinolone Acetonide versus saline or placebo, and the main outcome is pain on the Visual Analogue Scale at weeks 2, 4, and 12.[1]
In frozen shoulder, the study compares physical therapy, corticosteroid injection, and the combination of both, with the Shoulder Pain and Disability Index as the main result.[1]
For chronic shoulder pain, one trial compares corticosteroid nerve block with pulsed radiofrequency and uses SPADI to measure pain and disability.[1]
The rheumatoid arthritis trials look at whether corticosteroid bridging or a tailored treatment plan can help patients reach remission or lower disease activity, using measures such as DAS28-CRP and disease activity over time.[1]
The thumb joint osteoarthritis study measures pain during daily activities after 4 and 12 weeks to see whether steroid injections work better than saline or occupational therapy.[1]
Ear and eye studies
One Phase 2 study looks at persistent sudden sensorineural hearing loss and tests intracochlear Triamcinolone Acetonide, which means the treatment is placed inside the cochlea, the hearing part of the inner ear.[1]
The main outcome in that study is the change in hearing threshold on day 30, measured in the frequencies most affected by hearing loss.[1]
Other studies in the source data involve eye-related conditions such as postoperative recovery after vitrectomy and geographic atrophy, where Triamcinolone Acetonide appears as part of the treatment or control setup.[1]
In the vitrectomy study, the main question is whether NSAID eye drops reduce the risk of increased eye pressure compared with steroid eye drops after surgery.[1]
In geographic atrophy studies, the main outcomes include change in lesion area and long-term safety and tolerability, with retinal imaging and eye examinations used for follow-up.[1]
Skin and soft tissue studies
Some trials focus on skin disease and painful scar tissue, including hidradenitis suppurativa, atopic dermatitis, and post-surgical scar pain.[1]
In hidradenitis suppurativa, Triamcinolone Acetonide is used as an intralesional treatment in Phase 3 studies that compare treatment plans and measure HiSCR50 at week 16.[1]
HiSCR50 means at least a 50% drop in abscess and inflammatory nodule count, without more draining tunnels or fistulae than at the start of the study.[1]
For post-surgical scar pain, one Phase 3 study compares botulinum toxin with corticosteroid injection and uses the Numerical Rating Scale for pain as the main outcome.[1]
In the atopic dermatitis study in children and adolescents, Triamcinolone Acetonide appears as a cutaneous treatment option alongside other treatments in a large Phase 3 trial that also measures skin improvement and drug exposure data.[1]
Pediatric and surgical studies
Some studies include children, such as the trial on strictures after esophageal atresia repair, where local steroid injections are tested to see whether they can reduce the number of dilatations needed over time.[1]
That study is a low-intervention trial and focuses on the number of dilatations needed within 28-day intervals up to 6 months after the study procedure.[1]
Other studies include adolescents and adults, such as the birch pollen allergy trial and the atopic dermatitis trial, showing that the age range changes based on the condition being studied.[1]
The carpal tunnel syndrome study compares an injection-first strategy with surgery-first care and measures success after one year using the Boston Carpal Tunnel Questionnaire symptom score.[1]
What the trials measure
The main outcomes vary by disease, but they often focus on patient-reported symptoms, function, or disease control.[1]
Pain scores: Several studies use pain scales such as VAS or NRS to see whether symptoms improve after treatment.[1]
Function scores: Trials in shoulder and hand disease use tools like SPADI or the Boston Carpal Tunnel Questionnaire to measure daily function and symptom burden.[1]
Hearing outcomes: The hearing loss study measures change in hearing threshold using audiometry, which is a hearing test.[1]
Disease control: Rheumatoid arthritis and hidradenitis suppurativa studies measure remission or response rates to show whether the condition is getting better.[1]
Safety: Some trials measure adverse events, lab tests, eye pressure, or other safety checks to understand how well the treatment is tolerated in the study setting.[1]
Who the trials include
The target populations are different across studies and include adults with rheumatoid arthritis, adults with shoulder or hand pain, children with esophageal strictures, adolescents and adults with allergy or skin disease, and patients with sudden hearing loss.[1]
Some studies require a very specific diagnosis, such as persistent sudden sensorineural hearing loss after unsuccessful conservative therapy, unilateral Menière’s disease, or fibromyalgia with trapezius myofascial pain.[1]
Other studies include broader groups, such as people with hidradenitis suppurativa, atopic dermatitis, or rheumatoid arthritis according to 2010 criteria.[1]
Overall, the trial data show that Triamcinolone Acetonide is being studied in many different patient groups, with each trial designed around one main health problem and one main outcome.[1]
